ReveraGen Recruiting Young Boys with Duchenne

 

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy

This study will evaluate the safety and tolerability of a new steroid-like medication called vamorolone in boys with Duchenne ages ≥ 4 years and < 7 years. Enrolled participants will take the study medication for 14 days followed by a 14 day follow-up period. The potential effectiveness of vamorolone in treating Duchenne will also be explored.

This trial is sponsored by ReveraGen BioPharma, Inc.

There are trial sites in the US, Canada, the UK and Israel.

Please visit ClinicalTrials.gov for additional details, or listen to the ReveraGen webinar from January 18, 2017.

You may also contact Andrea Smith, MS at This email address is being protected from spambots. You need JavaScript enabled to view it.

Posted 12/8/2016; Updated 2/3/2017